Nodal maximum standardised uptake value improves PSMA ‐ PET / CT ‐based nodal staging in intermediate‐ and high‐risk prostate cancer
BJU International · 2026-07 · 138 (1) · 133-143
DOI: 10.1111/bju.70293 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift BJU International, online erschienen am 20.04.2026. Verfasst von Alexandra S Bruins Slot und 31 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, St. Antonius Hospital, Nieuwegein/Utrecht, The Netherlands. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Positron Emission Tomography Computed Tomography, Lymphatic Metastasis, Lymph Nodes. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objectives
To evaluate whether nodal maximum standardised uptake value (SUV max ) improves the positive predictive value (PPV) of prostate‐specific membrane antigen (PSMA) positron emission tomography (PET)/computerised tomography (CT) for detecting lymph node invasion (LNI) in prostate cancer (PCa), and to develop clinical decision tools to guide decision‐making for patients with low‐ and high‐volume nodal disease. Patients and Methods This international multicentre study included patients with histopathologically confirmed PCa who underwent preoperative PSMA‐PET and robot‐assisted radical prostatectomy with extended pelvic lymph node dissection (2016–2023). Sensitivity, specificity, PPV, and negative predictive value (NPV) for LNI detection were calculated, defining a positive test as non‐physiological PSMA uptake classified according to the Prostate Cancer Molecular Imaging Standardised Evaluation (PROMISE) molecular imaging Tumour‐Node‐Metastasis (miTNM) system. Receiver operating curves analysis identified optimal nodal SUV max cut‐offs for pelvic LNI. Logistic regression assessed predictors for pathological N1 stage (pN1) and high‐volume nodal disease (four or more positive nodes). Clinical decision tools were developed to stratify patients into three risk groups for pN1 and high‐volume nodal disease.
Results
A total of 521 patients were included, with a median (interquartile range) age of 66 (61–71) years and prostate‐specific antigen (PSA) level of 9.9 (6.6–17.0) ng/mL. The PSMA‐PET showed 45.0% sensitivity, 94.3% specificity, 64.7% PPV, and 88.3% NPV for LNI detection. Adding nodal SUV max ≥4.9 improved the PPV to 81.1% and sensitivity to 71.4% and, combined with a PSA level ≥10 ng/mL, magnetic resonance imaging (MRI) T‐stage ≥T3a, and miT‐stage ≥T3a, identified 95% of pN1 cases in the high‐risk group. High‐volume nodal disease was found in 3.8%, including 1.1% in miN0 patients. Nodal SUV max ≥7.2, MRI T‐stage ≥T3a, and miN2 (multiple suspicious LNs) were predictors for high‐volume nodal disease and, combined in a clinical decision tool, excluded all low‐risk patients for high‐volume nodal disease.
Conclusion
Nodal SUV max improves PPV of PSMA‐PET for nodal staging and aids in excluding high‐volume nodal disease. Clinical decision tools integrating nodal SUV max with relevant clinical parameters demonstrate potential to guide individualised nodal management. These findings warrant external validation in larger cohorts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, St. Antonius Hospital, Nieuwegein/Utrecht, The Netherlands.
- Department of Nuclear Medicine, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands.
- Department of Nuclear Medicine, St. Antonius Hospital, Nieuwegein/Utrecht, The Netherlands.
- Department of Urology, Indiana University Medical Center, Indianapolis, IN, USA.
- Department of Radiology and Imaging Sciences, Indiana University Medical Center, Indianapolis, IN, USA.
- Department of Urology, University Hospital Essen, Essen German Cancer Consortium (DKTK) University Hospital Essen, Essen, Germany.
ORCID-Profile: Alexandra S Bruins Slot, Clinton D Bahler, Peter Ka-Fung Chiu, Pawel Rajwa, Akihiro Matsukawa, Francesco Montorsi, Giorgio Gandaglia
Zitieren
APA
Bruins Slot, A. S., Sweere, V., Heetman, J. G., Hermsen, R., Wever, L., Lavalaye, J., Vinken, M., Bahler, C. D., Tann, M., Kesch, C., Telli, T., Fendler, W. P., Chiu, P. K., Wu, K. K., Zattoni, F., Evangelista, L., Ceci, F., Miszczyk, M., Rajwa, P., …, & European Association of Urology‐Young Academic Urologists (EAU‐YAU) Prostate Cancer Working Group (2026). Nodal maximum standardised uptake value improves PSMA ‐ PET / CT ‐based nodal staging in intermediate‐ and high‐risk prostate cancer. BJU International, 138(1), 133-143. https://doi.org/10.1111/bju.70293
Vancouver
Bruins Slot AS, Sweere V, Heetman JG, Hermsen R, Wever L, Lavalaye J, et al. Nodal maximum standardised uptake value improves PSMA ‐ PET / CT ‐based nodal staging in intermediate‐ and high‐risk prostate cancer. BJU International. 2026;138(1):133-143. doi:10.1111/bju.70293
BibTeX
@article{BruinsSlot2026,
author = {Bruins Slot, Alexandra S and Sweere, Vera and Heetman, Joris G and Hermsen, Rick and Wever, Lieke and Lavalaye, Jules and Vinken, Maarten and Bahler, Clinton D and Tann, Mark and Kesch, Claudia and Telli, Tugce and Fendler, Wolfgang P and Chiu, Peter Ka-Fung and Wu, Kwan Kit and Zattoni, Fabio and Evangelista, Laura and Ceci, Francesco and Miszczyk, Marcin and Rajwa, Pawel and Matsukawa, Akihiro and Fazekas, Tamás and Barletta, Francesco and Briganti, Alberto and Montorsi, Francesco and Gandaglia, Giorgio and Van Basten, Jean-Paul A and Van Melick, Harm H E and Van den Bergh, Roderick C N and Marra, Giancarlo and Soeterik, Timo F W and Scheltema, Matthijs J V and European Association of Urology‐Young Academic Urologists (EAU‐YAU) Prostate Cancer Working Group, European Association of Urology‐Young Academic Urologists (EAU‐YAU) Prostate Cancer Working Group},
title = {Nodal maximum standardised uptake value improves PSMA ‐ PET / CT ‐based nodal staging in intermediate‐ and high‐risk prostate cancer},
journal = {BJU International},
year = {2026},
volume = {138},
number = {1},
pages = {133--143},
doi = {10.1111/bju.70293}
}
EUVIMED